Mycovia Pharmaceuticals, INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersDurham, NC
US patents21
SAM.gov UEIMFPUBFBD4ZX1
CAGE code7B9J7
Incorporated inNC
- biopharmaceuticals
- VIVJOA
- oteseconazole capsules
- 150 mg
- under-addressed medical conditions
- therapeutic innovations
- advancing treatments
Named on the company’s own website, read JUL 29, 2026
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
21 US patents granted 2018–2022, 3 of them in the five years to SEP 2025.
Organic fine chemistry 13Pharmaceuticals 8
- Metalloenzyme inhibitor compoundsUS 11,247,981 · granted FEB 15, 2022
- Antifungal compoundsUS 11,051,514 · granted JUL 6, 2021
- Antifungal compound processUS 10,836,740 · granted NOV 17, 2020
- Antifungal compound processUS 10,745,378 · granted AUG 18, 2020
- Antifungal compounds and processes for makingUS 10,676,459 · granted JUN 9, 2020
Newest 5 shown · Granted to Mycovia Pharmaceuticals, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Mycovia Pharmaceuticals, INC | Durham | NC | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.